The Insider Stuart Arbuckle Sold 6459 shares of Vertex Pharmaceuticals (VRTX); J Sainsbury plc (LON:SBRY) Had 6 Bulls

An insider of the company Vertex Pharmaceuticals Inc Ma, Stuart Arbuckle also its EVP\Chief Commercial Officer, disclosed his insider activities with the U.S. Security & Exchange Commission on February 28, 2018. As published in the document, Stuart had sold 6,459 shares of the ‘s company. The total insider trading trade was worth $1,091,571 U.S. Dollars. At the time of the transaction the price of a share was $169.0. Stuart is trying to silently decrease his company’s share, same as he did in the last month. He unloaded another 14,700 shares worth $2,365,451 USD. This outstanding transaction will probably draw attention, as Stuart Arbuckle right now has 0.02% of the total market cap of the company.

Among 21 analysts covering Sainsbury J PLC (LON:SBRY), 6 have Buy rating, 3 Sell and 12 Hold. Therefore 29% are positive. Sainsbury J PLC had 263 analyst reports since July 24, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Tuesday, October 20 by Deutsche Bank. As per Friday, June 17, the company rating was maintained by Societe Generale. On Friday, June 30 the stock rating was maintained by HSBC with “Reduce”. The rating was maintained by Deutsche Bank with “Hold” on Wednesday, December 13. The firm earned “Neutral” rating on Wednesday, November 11 by Nomura. The stock of J Sainsbury plc (LON:SBRY) has “Sell” rating given on Thursday, January 12 by Goldman Sachs. Deutsche Bank maintained the shares of SBRY in report on Wednesday, October 25 with “Hold” rating. On Thursday, November 12 the stock rating was maintained by Jefferies with “Hold”. As per Friday, January 15, the company rating was maintained by JP Morgan. Deutsche Bank maintained J Sainsbury plc (LON:SBRY) rating on Friday, November 6. Deutsche Bank has “Hold” rating and GBX 275 target. See J Sainsbury plc (LON:SBRY) latest ratings:

12/02/2018 Broker: Deutsche Bank Rating: Hold Old Target: GBX 265.00 New Target: GBX 265.00 Maintain
07/02/2018 Broker: Deutsche Bank Rating: Hold Maintain
24/01/2018 Broker: Shore Capital Rating: Buy Maintain
22/01/2018 Broker: Credit Suisse Rating: Neutral Old Target: GBX 295.00 New Target: GBX 275.00 DownGrade
18/01/2018 Broker: JP Morgan Rating: Underweight Old Target: GBX 200.00 New Target: GBX 200.00 Maintain
12/01/2018 Broker: Barclays Capital Rating: Equal Weight Old Target: GBX 240.00 New Target: GBX 240.00 Maintain
11/01/2018 Broker: Kepler Cheuvreux Rating: Hold Old Target: GBX 252.00 New Target: GBX 252.00 Maintain
10/01/2018 Broker: Shore Capital Rating: Buy Maintain
08/01/2018 Broker: Deutsche Bank Rating: Hold Maintain
04/01/2018 Broker: JP Morgan Rating: Underweight Old Target: GBX 200.00 New Target: GBX 200.00 Maintain

The stock decreased 0.05% or $0.0747 during the last trading session, reaching $165.8053. About 86,600 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since February 28, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $42.10 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 159.58 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

Investors sentiment increased to 1.62 in 2017 Q3. Its up 0.11, from 1.51 in 2017Q2. It improved, as 32 investors sold Vertex Pharmaceuticals Incorporated shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. Bluemountain Mgmt Lc accumulated 64,075 shares. Cibc Markets owns 0.08% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 57,531 shares. Sun Life Incorporated accumulated 1,851 shares. Bb&T Secs Limited Liability Corp has invested 0.02% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Eaton Vance Mgmt stated it has 0.25% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Tci Wealth Advisors has 10 shares. Carroll Fincl Assoc owns 46 shares. Fjarde Ap holds 0.17% or 58,372 shares. Chevy Chase Tru Holdings has 0.17% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Schwab Charles Invest Mgmt accumulated 0.12% or 925,075 shares. Advisor Partners Limited Co holds 5,051 shares. Botty Invsts Lc reported 9,991 shares or 0.48% of all its holdings. Walleye Trading Ltd Liability Company owns 3,502 shares for 0% of their portfolio. 13.27M are owned by Wellington Management Group Llp. Cibc Asset Management has invested 0.03% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Among 30 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Vertex Pharmaceuticals has $212.0 highest and $85.0 lowest target. $180.24’s average target is 8.71% above currents $165.8053 stock price. Vertex Pharmaceuticals had 97 analyst reports since July 31, 2015 according to SRatingsIntel. JMP Securities maintained it with “Market Outperform” rating and $211 target in Tuesday, February 13 report. The firm earned “Hold” rating on Wednesday, July 5 by Cowen & Co. Jefferies maintained it with “Buy” rating and $12600 target in Friday, June 9 report. The firm has “Outperform” rating by Cowen & Co given on Wednesday, July 19. BMO Capital Markets maintained the shares of VRTX in report on Tuesday, January 2 with “Buy” rating. H.C. Wainwright downgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, October 24 to “Neutral” rating. The firm has “Perform” rating by Oppenheimer given on Thursday, February 11. Stifel Nicolaus maintained the stock with “Buy” rating in Friday, September 29 report. The firm earned “Outperform” rating on Thursday, April 28 by RBC Capital Markets. On Tuesday, December 1 the stock rating was initiated by Stifel Nicolaus with “Buy”.

Since August 31, 2017, it had 0 insider purchases, and 42 sales for $117.99 million activity. SMITH IAN F had sold 75,000 shares worth $10.88 million. Graney Thomas also sold $116,511 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday, January 2. Another trade for 9,883 shares valued at $1.71 million was made by Silva Paul M on Thursday, February 1. On Monday, February 12 ALTSHULER DAVID sold $965,671 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 6,403 shares. Sachdev Amit sold $960,960 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday, January 23. Shares for $580,304 were sold by Chodakewitz Jeffrey on Monday, February 5. Shares for $614,001 were sold by Arbuckle Stuart A.

Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on April, 26. They expect $0.27 earnings per share, up 107.69% or $0.14 from last year’s $0.13 per share. VRTX’s profit will be $68.55 million for 153.52 P/E if the $0.27 EPS becomes a reality. After $0.32 actual earnings per share reported by Vertex Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -15.63% negative EPS growth.

J Sainsbury plc, together with its subsidiaries, engages in the food, general merchandise and clothing retailing, and financial services activities in the United Kingdom. The company has market cap of 5.68 billion GBP. It operates through four divisions: Retail – Food; Retail – General Merchandise & Clothing; Financial Services; and Property Investment. It has a 25.46 P/E ratio. The firm operates various store formats, including convenience stores and supermarkets, as well as offers organic produce under the Food to Go and FreeFrom names.

The stock increased 0.78% or GBX 2 during the last trading session, reaching GBX 259.7. About 2.95M shares traded. J Sainsbury plc (LON:SBRY) has 0.00% since February 28, 2017 and is . It has underperformed by 16.70% the S&P500.